Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>QuidelOrtho's third quarter 2024 financial results reveal a mixed performance, characterized by challenges and opportunities that investors should carefully weigh.</li><li>The reported revenue for the quarter stood at $727 million, a roughly 2% decline from the previous year, influenced by a decrease in COVID-19 and flu-related revenues compared to the prior year.</li><li>The company's adjusted EBITDA was $171 million, translating to an adjusted EBITDA margin of 23.5%, showing an improvement of 80 basis points over the previous year, primarily due to implemented cost-saving measures.</li></ul>

QuidelOrtho's third quarter 2024 financial results reveal a mixed performance, characterized by challenges and opportunities that investors should carefully weigh.The reported revenue for the quarter stood at $727 million, a roughly 2% decline from the previous year, influenced by a decrease in COVID-19 and flu-related revenues compared to the prior year.The company's adjusted EBITDA was $171 million, translating to an adjusted EBITDA margin of 23.5%, showing an improvement of 80 basis points over the previous year, primarily due to implemented cost-saving measures.

QuidelOrtho Corporation: Its Diverse Revenue Streams Surge – Discover the Lab Innovations Powering Growth! - Major Drivers

<ul><li>QuidelOrtho's second quarter 2024 financial results were guided by substantial review and restructuring as the new CEO, Brian Blaser, begins to imprint his strategy on the company’s operations.</li><li>The company reported $637 million in revenue and an adjusted EBITDA of $90 million.</li><li>These figures align with the company's expectations, indicating stable performance across its diverse geographical and operational spectrum.</li></ul>

QuidelOrtho's second quarter 2024 financial results were guided by substantial review and restructuring as the new CEO, Brian Blaser, begins to imprint his strategy on the company’s operations.The company reported $637 million in revenue and an adjusted EBITDA of $90 million.These figures align with the company's expectations, indicating stable performance across its diverse geographical and operational spectrum.

QuidelOrtho Corporation: These Are The 4 Biggest Factors Driving Our 'Buy' Rating! - Major Drivers

<ul><li>QuidelOrtho presented its First Quarter 2024 Financial Results, reflecting both strengths and challenges in its operations.</li><li>The company reported total revenue of $711 million, a decline from $846 million in the comparable prior year period, primarily due to reduced COVID-19 related revenues.</li><li>Despite this, excluded COVID-19 revenues showed a growth of 6% in constant currency across all regions, showcasing solid growth particularly in the EMEA and China regions.</li></ul>

QuidelOrtho presented its First Quarter 2024 Financial Results, reflecting both strengths and challenges in its operations.The company reported total revenue of $711 million, a decline from $846 million in the comparable prior year period, primarily due to reduced COVID-19 related revenues.Despite this, excluded COVID-19 revenues showed a growth of 6% in constant currency across all regions, showcasing solid growth particularly in the EMEA and China regions.

QuidelOrtho Corporation: How Are They Carrying Out The Expansion in Global Markets? - Major Drivers

<ul><li>QuidelOrtho reported total revenues of $3 billion for the full year 2023, a decrease of 26% from the previous year.</li><li>The drop was largely attributed to a lower respiratory season in 2023 compared to the prior year, specifically in COVID-19 related testing.</li><li>The company’s non-respiratory revenue segments, however, exhibited a growth of 5% for the year, suggesting potential opportunities in these areas.</li></ul>

QuidelOrtho reported total revenues of $3 billion for the full year 2023, a decrease of 26% from the previous year.The drop was largely attributed to a lower respiratory season in 2023 compared to the prior year, specifically in COVID-19 related testing.The company’s non-respiratory revenue segments, however, exhibited a growth of 5% for the year, suggesting potential opportunities in these areas.

QuidelOrtho Corporation: Initiation Of Coverage - How Long Will The Increasing Non-Respiratory Revenue Last? - Major Drivers

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>With multiple mutations, Omicron may require modifications in the existing vaccines. With fast mover advantage and superior efficacy, <a href="https://www.smartkarma.com/entities/moderna-inc" target="_blank" data-smartkarma-citation="entities:28744:1" rel="noopener">Moderna Inc (MRNA US)</a> seems to be a clear winner of the situation.</li>
<li>Moderna’s current expectation to deliver 2–3 billion doses in 2022 is likely to be revised upwards with the fast spread of Omicron vaccine and full approval of booster doses.</li>
<li>Moderna shares have reasonable valuation compared to its peers. Higher visibility into 2022 and beyond will lead to re-rating opportunity.</li>
</ul>


With multiple mutations, Omicron may require modifications in the existing vaccines. With fast mover advantage and superior efficacy, Moderna Inc (MRNA US) seems to be a clear winner of the situation.
Moderna’s current expectation to deliver 2–3 billion doses in 2022 is likely to be revised upwards with the fast spread of Omicron vaccine and full approval of booster doses.
Moderna shares have reasonable valuation compared to its peers. Higher visibility into 2022 and beyond will lead to re-rating opportunity.


Moderna (MRNA US): To Cash in on Omicron Fear

United States

QuidelOrtho Corporation provides health care services. The Company offers technologies and platforms to benefit customers with expanded access to clinical chemistry, immunoassay, molecular diagnostics, immunohematology, donor screening, and point-of-care diagnostics offerings.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

QuidelOrtho (QDEL US)

QuidelOrtho Corporation: Its Diverse Revenue Streams Surge – Discover the Lab Innovations Powering Growth! - Major Drivers

QuidelOrtho's third quarter 2024 financial results reveal a mixed performance, characterized by challenges and opportunities that investors should...

Baptista Research

QuidelOrtho Corporation: These Are The 4 Biggest Factors Driving Our 'Buy' Rating! - Major Drivers

QuidelOrtho's second quarter 2024 financial results were guided by substantial review and restructuring as the new CEO, Brian Blaser, begins to...

Baptista Research

QuidelOrtho Corporation: How Are They Carrying Out The Expansion in Global Markets? - Major Drivers

QuidelOrtho presented its First Quarter 2024 Financial Results, reflecting both strengths and challenges in its operations. The company reported...

Baptista Research

QuidelOrtho Corporation: Initiation Of Coverage - How Long Will The Increasing Non-Respiratory Revenue Last? - Major Drivers

QuidelOrtho reported total revenues of $3 billion for the full year 2023, a decrease of 26% from the previous year. The drop was largely...

Baptista Research

Moderna (MRNA US): To Cash in on Omicron Fear

Moderna is set to fly high on the continuous increasing demand for its Covid vaccine and rich pipeline beyond Covid. Emerging Omicron variant is...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)